Consolidation durvalumab

DRUG2 trials

Sponsors

Rachel Sanborn, Idris Bahce

Conditions

Lung CancerNon-small Cell CarcinomaNon-small Cell Lung Cancer Stage III

Phase 2

Durvalumab Followed by Chemoradiation and Consolidation Durvalumab for Stage III Non-small Cell Lung Cancer

TerminatedNCT04364048

Rachel SanbornLung Cancer, Non-small Cell Carcinoma

Start: 2020-06-18End: 2024-02-05Updated: 2024-12-20

Phase 4

Chemoradiotherapy With Surgery Followed by Consolidation Durvalumab

RecruitingNCT06908070

Idris BahceNon-small Cell Lung Cancer Stage III

Start: 2024-12-17End: 2028-12-17Target: 38Updated: 2026-08-20

Related Papers

Tremelimumab plus Durvalumab prior to Chemoradiotherapy in Unresectable, Locally Advanced Non–Small Cell Lung Cancer: The Induction Trial

Clinical Cancer Research2025-01-172 citations